Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis

References

• National Osteoporosis FoundationPhysician’s Guide to Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2003
   Google Scholar
• EastellRPathogenesis of postmenopausal osteoporosisRosenCJCompstonJELianJBASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism7th edWashington, DCAmerican Society for Bone and Mineral ResearchNew York, NY: Wiley InterScience2008259262
   Google Scholar
• US Department of Health and Human ServicesBone Health and Osteoporosis: A Report of the Surgeon GeneralRockville, MDUS Department of Health and Human Services, Office of the Surgeon General2004Available from: http://surgeongeneral.gov/library/bonehealth/index.html Accessed Mar 24, 2010.
   Google Scholar
• HarveyNDennisonECooperCOsteoporosis: impact on health and economicsNat Rev Rheumatol201069910520125177
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res20072246547517144789
   PubMed Web of Science ®Google Scholar
• EpsteinSUpdate of current therapeutic options for the treatment of postmenopausal osteoporosisClin Ther20062815117316678639
   PubMed Web of Science ®Google Scholar
• RussellRGGWattsNBEbetinoFHRogersMJMechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporos Int20081973375918214569
   PubMed Web of Science ®Google Scholar
• NancollasGHTangRPhippsRJNovel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatiteBone20063861762716046206
   PubMed Web of Science ®Google Scholar
• LawsonMAXiaZBarnettBLDifferences between bisphosphonates in binding affinities for hydroxyapatiteJ Biomed Mater Res B Appl Biomater20109211495519904734
   PubMed Web of Science ®Google Scholar
• DunfordJEThompsonKCoxonFPStructure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonatesJ Pharmacol Exp Ther200129623524211160603
   PubMed Web of Science ®Google Scholar
• DunfordJEKwaasiAARogersMJStructure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthaseJ Med Chem20085172187219518327899
   PubMed Web of Science ®Google Scholar
• SilvermanSLWattsNBDelmasPDLangeJLLindsayREffectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort studyOsteoporos Int200718253417106785
   PubMed Web of Science ®Google Scholar
• ReckerRRLewieckiEMMillerPDReiffelJSafety of bisphosphonates in the treatment of osteoporosisAm J Med2009122Suppl 2S22S3219187809
   PubMed Web of Science ®Google Scholar
• WattsNBDiabDLLong-term use of bisphosphosphonates [sic] in osteoporosisJ Clin Endocrinol Metab2010 Epub 2010 Feb 19. doi:10.1210/jc.2009-1947.
   Google Scholar
• BlackDMCummingsSRKarpfDBRandomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet1996348153515418950879
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDEEffect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA1998280207720829875874
   PubMed Web of Science ®Google Scholar
• PolsHAFelsenbergDHanleyDAMultinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study GroupOsteoporos Int1999946146810550467
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBGenantHKEffects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA19992821344135210527181
   PubMed Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOHRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int200011839110663363
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPDfor Hip Intervention Program Study GroupEffect of risedronate on the risk of hip fracture in elderly womenN Engl J Med200134433334011172164
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRfor HORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med20073561809182217476007
   PubMed Web of Science ®Google Scholar
• ChesnutCH3rdSkagAChristiansenCEffects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res2004191241124915231010
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBröllJEffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study GroupN Engl J Med199533322143714437477143
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDEBauerDCFracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research GroupJ Clin Endocrinol Metab20008541184124 Erratum in: J Clin Endocrinol Metab. 2001;86(2):938.11095442
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiGTherapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)20001211210746426
   PubMedGoogle Scholar
• RizzoliRGreenspanSLBoneGTwo-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosisJ Bone Miner Res2002171988199612412806
   PubMed Web of Science ®Google Scholar
• RouxCSeemanEEastellREfficacy of risedronate on clinical vertebral fractures within six monthsCurr Med Res Opin20042043343915119979
   PubMed Web of Science ®Google Scholar
• HarringtonJTSte-MarieLGBrandiMLRisedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosisCalcif Tissue Int20047412913514648009
   PubMed Web of Science ®Google Scholar
• HarrisSTWattsNBLiZChinesAAHanleyDABrownJPTwo-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosisCurr Med Res Opin200420757764 Erratum in: Curr Med Res Opin. 2004;20(10):1690.15140343
   PubMed Web of Science ®Google Scholar
• DelmasPDBenhamouCLManZMonthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsOsteoporos Int2008191039104518087660
   PubMed Web of Science ®Google Scholar
• DelmasPDMcClungMRZanchettaJREfficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisBone200842364217920005
   PubMed Web of Science ®Google Scholar
• WattsNBLindsayRLiZKasibhatlaCBrownJUse of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronateOsteoporos Int20031443744112730756
   PubMed Web of Science ®Google Scholar
• WattsNBBrownJClineGDelmasPDTwo-consecutive days-a-month risedronate 75 mg reduces vertebral fracture risk at one yearJ Bone Miner Res200722Suppl 1W373
   Google Scholar
• WattsNKlemesAWagnerLBrownJOnce-a-month risedronate 150 mg reduced vertebral fracture risk at one year in a historical control analysisJ Bone Miner Res200823Suppl 1SU403
   Google Scholar
• MillerPDMcClungMRMacoveiLMonthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyJ Bone Miner Res2005201315132216007327
   PubMed Web of Science ®Google Scholar
• ReginsterJYAdamiSLakatosPEfficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnn Rheum Dis20066565466116339289
   PubMed Web of Science ®Google Scholar
• DelmasPDAdamiSStrugalaCIntravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration studyArthritis Rheum2006541838184616729277
   PubMed Web of Science ®Google Scholar
• EismanJACivitelliRAdamiSEfficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA studyJ Rheumatol20083548849718260172
   PubMed Web of Science ®Google Scholar
• CranneyAWellsGAYetisirEIbandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient dataOsteoporos Int20092029129718663402
   PubMed Web of Science ®Google Scholar
• PazianasMEpsteinSZaidiMEvaluating the antifracture efficacy of bisphosphonatesRev Recent Clin Trials2009412213019463108
   PubMedGoogle Scholar
• LylesKWColon-EmericCSMagazinerJSZoledronic acid and clinical fractures and mortality after hip fractureN Engl J Med20073571799180917878149
   PubMed Web of Science ®Google Scholar
• Colón-EmericCSMesenbrinkPLylesKWPotential mediators of the mortality reduction with zoledronic acid after hip fractureJ Bone Miner Res201025919719580467
   PubMed Web of Science ®Google Scholar
• BollandMJGreyABGambleGDReidIREffect of osteoporosis treatment on mortality: a meta-analysisJ Clin Endocrinol Metab20109531174118120080842
   PubMed Web of Science ®Google Scholar
• RosenCJHochbergMCBonnickSLfor Fosamax Actonel Comparison Trial InvestigatorsTreatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind studyJ Bone Miner Res20052014115115619680
   PubMed Web of Science ®Google Scholar
• BonnickSSaagKGKielDPComparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two yearsJ Clin Endocrinol Metab200691726312637 Erratum in: J Clin Endocrinol Metab. 2007;92(8):3032.16636120
   PubMed Web of Science ®Google Scholar
• MillerPDEpsteinSSeddaratiFReginsterJYOnce-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION studyCurr Med Res Opin20082420721318042311
   PubMed Web of Science ®Google Scholar
• EmkeyRDelmasPDBologneseMEfficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) studyClin Ther200931475176119446148
   PubMed Web of Science ®Google Scholar
• WattsNBCooperCLindsayRRelationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture riskJ Clin Densitom2004725526115319494
   PubMed Web of Science ®Google Scholar
• DelmasPDSeemanEChanges in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapyBone20043459960415050889
   PubMed Web of Science ®Google Scholar
• EastellRBartonIHannonRAChinesAGarneroPDelmasPDRelationship of early changes in bone resorption to the reduction in fracture risk with risedronateJ Bone Miner Res2003181051105612817758
   PubMed Web of Science ®Google Scholar
• EnsrudKEBarrett-ConnorELSchwartzARandomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extensionJ Bone Miner Res2004191259126915231012
   PubMed Web of Science ®Google Scholar
• BlackDMSchwartzAVEnsrudKEEffects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trialJAMA20062962927293817190893
   PubMed Web of Science ®Google Scholar
• SorensenOHCrawfordGMMulderHLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone20033212012612633783
   PubMed Web of Science ®Google Scholar
• MellströmDDSörensenOHGoemaereSRouxCJohnsonTDChinesAASeven years of treatment with risedronate in women with postmenopausal osteoporosisCalcif Tissue Int20047546246815455188
   PubMed Web of Science ®Google Scholar
• DevogelaerJPBrownJPBurckhardtPZoledronic acid efficacy and safety over five years in postmenopausal osteoporosisOsteoporos Int2007181211121817516022
   PubMed Web of Science ®Google Scholar
• WattsNBChinesAOlszynskiWPFracture risk remain reduced one year after discontinuation of risedronateOsteoporos Int20081936537217938986
   PubMed Web of Science ®Google Scholar
• HannonRPurpleCKlemesAClineGEastellROffset of effects on bone resorption after 7 years of risedronate therapyECTS (European Calcified Tissue Society) 2009: 36th European Symposium on Calcified Tissues2009 May 23–27Vienna Abstract OP08.
   Google Scholar
• GreyABollandMJWattieDHorneAGambleGReidIRThe antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal womenJ Clin Endocrinol Metab200994253854419050050
   PubMed Web of Science ®Google Scholar
• IMS HealthNPA Plus™ May 2006Norwalk, CTIMS Health Inc2006
   Google Scholar
• GreenJRRogersMPharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorptionDrug Dev Res200255210224doi:10.1002/ddr.10071.
   Web of Science ®Google Scholar
• PapapoulosSECremersSCProlonged bisphosphonate release after treatment in childrenN Engl J Med2007356101075107617347467
   PubMed Web of Science ®Google Scholar
• LufkinEGArguetaRWhitakerMDPamidronate: an unrecognized problem in gastrointestinal tolerabilityOsteoporos Int199443203227696825
   PubMed Web of Science ®Google Scholar
• de GroenPCLubbeDFHirschLJEsophagitis associated with the use of alendronateN Engl J Med199633514101610218793925
   PubMed Web of Science ®Google Scholar
• Fosamax® (alendronate sodium) prescribing informationWhitehouse Station, NJMerck and Co. Inc32010Available from: www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf Accessed Mar 24, 2010.
   Google Scholar
• Actonel® (risedronate sodium) prescribing informationCincinnati, OHProcter and Gamble Pharmaceuticals, Inc122009Available from: http://www.actonel.com/global/prescribing_information.pdf Accessed Mar 24, 2010.
   Google Scholar
• Boniva® (ibandronate sodium) prescribing informationSouth San Francisco, CAGenentech USA Inc12010 Available from: http://www.gene.com/gene/products/information/boniva/pdf/pi.pdf. Accessed Mar 24, 2010.
   Google Scholar
• LanzaFLHuntRHThomsonABProvenzaJMBlankMAEndoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal womenGastroenterology2000119363163810982755
   PubMed Web of Science ®Google Scholar
• StrampelWEmkeyRCivitelliRSafety considerations with bisphosphonates for the treatment of osteoporosisDrug Saf20073075576317722968
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDEnsrudKUpper gastrointestinal tract safety profile of alendronate: the Fracture Intervention TrialArch Intern Med200016051752510695692
   PubMed Web of Science ®Google Scholar
• TaggartHBologneseMALindsayRUpper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trialsMayo Clin Proc200277262270 Erratum in: Mayo Clin Proc. 2002;77(6):601.11888030
   PubMed Web of Science ®Google Scholar
• Boniva® (ibandronate sodium) injection prescribing informationSouth San Francisco, CAGenentech USA Inc32010 Available from: http://www.gene.com/gene/products/information/boniva/pdf/Injection_pi.pdf. Accessed Mar 24, 2010.
   Google Scholar
• Reclast® (zoledronic acid) prescribing informationStein, SwitzerlandNovartis Pharma Stein AG52009 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/reclast.pdf. Accessed Mar 24, 2010.
   Google Scholar
• EpsteinSGeusensPFisherJEDisintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacyJ Appl Res200552253265 Available from: http://www.jarcet.com/articles/Vol5Iss2/index.htm.
   Google Scholar
• EpsteinSCryerBRagiSDisintegration/dissolution profiles of copies of Fosamax (alendronate)Curr Med Res Opin200319781789 Erratum in: Curr Med Res Opin. 2004;20(4):575.14687450
   PubMed Web of Science ®Google Scholar
• DansereauRJCrailDJPerkinsACIn vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implicationsCurr Med Res Opin2008241137114518334082
   PubMed Web of Science ®Google Scholar
• DansereauRJCrailDJPerkinsACIn vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the USCurr Med Res Opin20092544945219192989
   PubMed Web of Science ®Google Scholar
• GrimaDTPapaioannouAThompsonMFPasqualeMKAdachiJDGreater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysisOsteoporos Int200819568769718008100
   PubMed Web of Science ®Google Scholar
• RingeJDMöllerGDifferences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysisRheumatol Int200930213221
   PubMed Web of Science ®Google Scholar
• MillerPDRouxCBoonenSBartonIPDunlapLEBurgioDESafety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trialsJ Bone Miner Res2005202105211516294264
   PubMed Web of Science ®Google Scholar
• MillerPDMidayRKlemesARamseyDRenal safety across a wide range of dosing regimens of risedronateJ Bone Miner Res200823Suppl 1SA402
   Google Scholar
• JamalSABauerDCEnsrudKEAlendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention TrialJ Bone Miner Res20072250350817243862
   PubMed Web of Science ®Google Scholar
• PerazellaMAMarkowitzGSBisphosphonate nephrotoxicityKidney Int200874111385139318685574
   PubMed Web of Science ®Google Scholar
• AdamiSBhallaAKDorizziRThe acute-phase response after bisphosphonate administrationCalcif Tissue Int19874163263313124942
   PubMed Web of Science ®Google Scholar
• FrijlinkWBBijvoetOLte VeldeJHeynenGTreatment of Paget’s disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)Lancet19791812079980386042
   PubMed Web of Science ®Google Scholar
• ThompsonKRogersMJStatins prevent bisphosphonate-induced γ, δ-T-cell proliferation and activation in vitroJ Bone Miner Res20041927828814969398
   PubMed Web of Science ®Google Scholar
• CoxonFPThompsonKRogersMJRecent advances in understanding the mechanism of action of bisphosphonatesCurr Opin Pharmacol20066330731216650801
   PubMed Web of Science ®Google Scholar
• HewittRELissinaAGreenAESlayESPriceDASewellAKThe bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClin Exp Immunol2005139110111115606619
   PubMed Web of Science ®Google Scholar
• RoelofsAJJauhiainenMMönkkönenHRogersMJMönkkönenJThompsonKPeripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPPBr J Haematol2009144224525019016713
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA)Severe Pain with Osteoporosis DrugsSilver Spring, MDFDA2008 Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/psn/transcript.cfm?show=79#2. Accessed Mar 24, 2010.
   Google Scholar
• PazianasMCompstonJHuangCLAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res201025121020091928
   PubMed Web of Science ®Google Scholar
• CummingsSRSchwartzAVBlackDMAlendronate and atrial fibrillationN Engl J Med20073561895189617476024
   PubMed Web of Science ®Google Scholar
• KaramRCammJMcClungMYearly zoledronic acid in postmenopausal osteoporosisN Engl J Med200735771271317703529
   PubMed Web of Science ®Google Scholar
• LewieckiEMCooperCThompsonEHartlFMehtaDPapapoulosSEIbandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trialsInt J Clin PractIn Press 2010.
   Google Scholar
• HeckbertSRLiGCummingsSRSmithNLPsatyBMUse of alendronate and risk of incident atrial fibrillation in womenArch Intern Med200816882683118443257
   PubMed Web of Science ®Google Scholar
• SørensenHTChristensenSMehnertFUse of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ200833681381618334527
   PubMed Web of Science ®Google Scholar
• AbrahamsenBEikenPBrixenKAtrial fibrillation in fracture patients treated with oral bisphosphonatesJ Intern Med2009265558159219141097
   PubMed Web of Science ®Google Scholar
• GrossoADouglasIHingoraniAMacAllisterRSmeethLOral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysisPLoS ONE200943e472019266096
   PubMed Web of Science ®Google Scholar
• LokeYKJeevananthamVSinghSBisphosphonates and atrial fibrillation: systematic review and meta-analysisDrug Saf20093221922819338379
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA)Update of Safety Review Follow-up to the Oct 1, 2007 Early Communication about the Ongoing Safety Review of BisphosphonatesSilver Spring, MDFDA2008 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm136201.htm. Accessed Mar 24, 2010.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency (MHRA)Bisphosphonates: atrial fibrillationDrug Safety Update20081124London, UKMHRAAvailable from: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON020566 Accessed Mar 24, 2010.
   Google Scholar
• European Medicines Agency (EMEA)Aclasta (zoledronic acid): European Public Assessment Report, revision 9LondonEMEA782009 Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/aclasta/aclasta.htm. Accessed Mar 24, 2010.
   Google Scholar
• MalikARCampbellSHTomaNMBilateral acute anterior uveitis after alendronateBr J Ophthalmol200286144312446386
   PubMed Web of Science ®Google Scholar
• FraunfelderFWFraunfelderFTBisphosphonates and ocular inflammationN Engl J Med20033481187118812646685
   PubMed Web of Science ®Google Scholar
• BendersonDKarakunnelJKathuriaSBadrosAScleritis complicating zoledronic acid infusionClin Lymphoma Myeloma2006714514717026827
   PubMedGoogle Scholar
• MooreMMBeithJMAcute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancerMed J Aust200818837037118341464
   PubMed Web of Science ®Google Scholar
• BanalFBriotKAyoubGDougadosMRouxCUnilateral anterior uveitis complicating zoledronic acid therapy in prostate cancerJ Rheumatol200835122458245919040323
   PubMed Web of Science ®Google Scholar
• SharmaNSOoiJLMasselosKHooperMJFrancisICZoledronic acid infusion and orbital inflammatory diseaseN Engl J Med2008359131410141118815406
   PubMed Web of Science ®Google Scholar
• WysowskiDKReports of esophageal cancer with oral bisphosphonate useN Engl J Med2009360899019118315
   PubMed Web of Science ®Google Scholar
• NewcombPATrentham-DietzAHamptonJMBisphosphonates for osteoporosis treatment are associated with reduced breast cancer riskBr J Cancer2010102579980220160722
   PubMed Web of Science ®Google Scholar
• CooperCSteinbuchMStevensonRMidayRWattsNBThe epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UKOsteoporos Int201021456957719547906
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• PazianasMMillerPBlumentalsWABernalMKothawalaPA review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristicsClin Ther200781548155817919538
   PubMedGoogle Scholar
• KhanAASandorGKDoreEBisphosphonate associated osteonecrosis of the jaw. Canadian Task Force on Osteonecrosis of the JawJ Rheumatol200936347849019286860
   PubMed Web of Science ®Google Scholar
• WooSBHellsteinJWKalmarJRSystematic review: bisphosphonates and osteonecrosis of the jawsAnn Intern Med200614475376116702591
   PubMed Web of Science ®Google Scholar
• WimalawansaSJInsight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical managementExpert Opin Drug Saf20087449151218613812
   PubMed Web of Science ®Google Scholar
• American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial SurgeonsJ Oral Maxillofac Surg20076536937617307580
   PubMed Web of Science ®Google Scholar
• BoydeAKingsmillVJAge changes in boneGerodontology199815253410530168
   PubMedGoogle Scholar
• AgarwalaSShahSJoshiVRThe use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight yearsJ Bone Joint Surg Br20099181013101819651826
   PubMedGoogle Scholar
• AllenMRBurrDBMandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatmentJ Oral Maxillofac Surg20086698799418423290
   PubMed Web of Science ®Google Scholar
• SonisSTWatkinsBALyngGDLermanMAAndersonKCBony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patientsOral Oncol20094516417218715819
   PubMed Web of Science ®Google Scholar
• AllenMRAnimal models of osteonecrosis of the jawJ Musculoskelet Neuronal Interact2007735836018094512
   PubMedGoogle Scholar
• NovinceCMWardBBMcCauleyLKOsteonecrosis of the jaw: an update and review of recommendationsCells Tissues Organs200918927528318765930
   PubMed Web of Science ®Google Scholar
• ReidIROsteonecrosis of the jaw – Who gets it, and whyBone20094441018948230
   PubMed Web of Science ®Google Scholar
• BaussFPfisterTPapapoulosSIbandronate uptake in the jaw is similar to long bones and vertebrae in the ratJ Bone Miner Metab200826440640818600409
   PubMed Web of Science ®Google Scholar
• SilvermanSLLandesbergROsteonecrosis of the jaw and the role of bisphosphonates: a critical reviewAm J Med2009122Suppl 2S33S4519187811
   PubMed Web of Science ®Google Scholar
• LehrerSMontazemARamanathanLNormal serum bone markers in bisphosphonate-induced osteonecrosis of the jawsOral Surg Oral Med Oral Pathol Oral Radiol Endod200810638939118554944
   PubMed Web of Science ®Google Scholar
• LehrerSMontazemARamanathanLBisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate geneJ Oral Maxillofac Surg20096715916119070762
   PubMed Web of Science ®Google Scholar
• GrbicJTLandesbergRLinSQfor Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial Research GroupIncidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trialJ Am Dent Assoc20081391324018167382
   PubMed Web of Science ®Google Scholar
• American Dental Association “Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws: June 2004” Available from: http://www.ada.org/sections/professionalResources/pdfs/topics_osteonecrosis_whitepaper.pdf Accessed Apr 8, 2010.
   Google Scholar
• GohSKYangKYKohJSSubtrochanteric insufficiency fractures in patients on alendronate therapy: a cautionJ Bone Joint Surg Br20078934935317356148
   PubMed Web of Science ®Google Scholar
• LenartBALorichDGLaneJMAtypical fractures of the femoral diaphysis in postmenopausal women taking alendronateN Engl J Med20083581304130618354114
   PubMed Web of Science ®Google Scholar
• KwekEBKGohSKKohJSBPngMAHoweTSAn emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapyInjury20083922423118222447
   PubMed Web of Science ®Google Scholar
• NeviaserASLaneJMLenartBAEdobor-OsulaFLorichDGLow-energy femoral shaft fractures associated with alendronate useJ Orthop Trauma20082234635018448990
   PubMed Web of Science ®Google Scholar
• AbrahamsenBEikenPEastellRSubtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort studyJ Bone Miner Res20092461095110219113931
   PubMed Web of Science ®Google Scholar
• BoonenAWakefieldDHuntjensKvan HeldenSGeusensPThe prevalence of subtrochanteric fractures in patients older than 50 years presenting with a clinical vertebral or non-vertebral fractureJ Bone Miner Res200823Suppl 1 Abstract Su390.
   Google Scholar
• SomfordMPDraijerFWThomassenBJChavassieuxPMBoivinGPapapoulosSEBilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragilityJ Bone Miner Res200924101736174019419297
   PubMed Web of Science ®Google Scholar
• WeinsteinRSRobersonPKManolagasSCGiant osteoclast formation and long-term oral bisphosphonate therapyN Engl J Med20093601536219118304
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA)Committee for Medicinal Products for Human Use February 2009 Plenary Meeting Monthly ReportLondonEMEA2262009 Available from: http://www.emea.europa.eu/pdfs/human/press/pr/9779509en.pdf Accessed Mar 24, 2010.
   Google Scholar
• Medicines and Healthcare products Regulatory Agency (MHRA)Bisphosphonates: atypical stress fracturesDrug Safety Update2009288London, UKMHRA Available from: http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211. Accessed Mar 24, 2010.
   Google Scholar
• MashibaTHiranoTTurnerCHForwoodMRJohnstonCCBurrDBSuppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog ribJ Bone Miner Res20001561362010780852
   PubMed Web of Science ®Google Scholar
• MashibaTTurnerCHHiranoTForwoodMRJohnstonCCBurrDBEffects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beaglesBone20012852453111344052
   PubMed Web of Science ®Google Scholar
• AllenMRIwataKPhippsRBurrDBAlterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronateBone20063987287916765660
   PubMed Web of Science ®Google Scholar
• StepanJJBurrDBPavoILow bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosisBone20074133783385
   Web of Science ®Google Scholar
• ChapurlatRDArlotMBurt-PichatBMicrocrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy studyJ Bone Miner Res2007221502150917824840
   PubMed Web of Science ®Google Scholar
• ChavassieuxPMArlotMERedaCWeiLYatesAJMeunierPJHistomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosisJ Clin Invest1997100147514809294113
   PubMed Web of Science ®Google Scholar
• EriksenEFMelsenFSodEBartonIChinesAEffects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosisBone20023162062512477578
   PubMed Web of Science ®Google Scholar
• ReckerRRWeinsteinRSChesnutCHIIIHistomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE studyOsteoporos Int20041523123714727011
   PubMedGoogle Scholar
• ReckerRRDelmasPDHalseJEffects of intravenous zoledronic acid once yearly on bone remodeling and bone structureJ Bone Miner Res20082361617892374
   PubMed Web of Science ®Google Scholar
• BrownJPPrinceRLDealCComparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJ Bone Miner Res200924115316118767928
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRfor the FREEDOM TrialDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• KhoslaSIncreasing options for the treatment of osteoporosisN Engl J Med2009361881882019671654
   PubMed Web of Science ®Google Scholar
• SeemanETo stop or not to stop, that is the questionOsteoporos Int200920218719519096746
   PubMed Web of Science ®Google Scholar
• EttingerBSan MartinJCransGPavoIDifferential effects of teriparatide on BMD after treatment with raloxifene or alendronateJ Bone Miner Res200419574575115068497
   PubMed Web of Science ®Google Scholar
• BlackDMGreenspanSLEnsrudKEThe effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosisN Engl J Med20033491207121514500804
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSHayesAHunzelmanJLWylandJJLeeHNeerRMThe effects of parathyroid hormone, alendronate, or both in men with osteoporosisN Engl J Med20033491216122614500805
   PubMed Web of Science ®Google Scholar
• FinkelsteinJSLederBZBurnettSAEffects of teriparatide, alendronate, or both on bone turnover in osteoporotic menJ Clin Endocrinol Metab2006912882288716684825
   PubMed Web of Science ®Google Scholar
• Obermayer-PietschBMMarinFMcCloskeyEVfor EUROFORS InvestigatorsEffects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatmentJ Bone Miner Res200823101591160018505369
   PubMed Web of Science ®Google Scholar
• BoonenSMarinFObermayer-PietschBfor EUROFORS InvestigatorsEffects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosisJ Clin Endocrinol Metab20089385286018160462
   PubMed Web of Science ®Google Scholar
• EastellRNickelsenTMarinFSequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)J Bone Miner Res200924472673619049337
   PubMed Web of Science ®Google Scholar
• MillerPDDelmasPDLindsayREarly responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronateJ Clin Endocrinol Metab2008933785379318682511
   PubMed Web of Science ®Google Scholar
• ChevalierYQuekEBorahBBiomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral bodyBone2010461414819800436
   PubMed Web of Science ®Google Scholar
• GreenspanSField-MunvesEToninoRTolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled studyMayo Clin Proc2002771044105212374248
   PubMed Web of Science ®Google Scholar
• CryerBMillerPPetruschkeRAChenEGebaGPPappAEUpper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug useAliment Pharmacol Ther20052159960715740544
   PubMed Web of Science ®Google Scholar